Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PVC · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| PVC (daily for 21 days, 7 days off) | DRUG | - |
| PVC (twice weekly) | DRUG | - |
Inclusion Criteria: Generally healthy postmenopausal women with symptoms of atrophic vaginitis including vaginal dryness, vaginal itching, vaginal burning, and/or painful intercourse. The subject must have a clinical diagnosis of atrophic vaginitis and an intact uterus. Exclusion Criteria: Women...
PVC is being studied for the treatment of atrophic vaginitis, a condition involving atrophy and inflammation of the vaginal tissue. It is a small molecule developed by Pfizer, Inc. in the endocrine therapeutic area. The clinical program has focused on women aged 45 years and older.
PVC is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer sponsored the Phase 3 clinical trial evaluating the therapy in atrophic vaginitis. The program includes one completed study conducted in the United States and Canada.
PVC is in Phase 3 clinical development for atrophic vaginitis. One Phase 3 trial has been completed, and no trials are currently active. The completed study enrolled 480 participants and was randomized and double blind.
PVC has been evaluated in the Phase 3 trial NCT00137371, titled Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis. The trial enrolled 480 female participants aged 45 years and older, was randomized and double blind, and was conducted in the United States and Canada. It is now completed.
Yes, PVC (daily for 21 days, 7 days off) refers to the same asset as PVC. The parenthetical describes the dosing schedule used for this Pfizer-developed small molecule in its atrophic vaginitis program. Readers searching either name are looking at the same investigational therapy.